CoChat
Sign Up
Cited by 56Pregnancy and Medication ImpactSchizophrenia research and treatmentMaternal Mental Health During Pregnancy and Postpartum

Use of Antipsychotics in the Management of Schizophrenia during Pregnancy

Trixler, M??ty??s, G??ti, ??gnes, Fekete, S??ndor, T??nyi, Tam??s·2005·Drugs
DOI 10.2165/00003495-200565090-00002
Open this paper in CoChat — free account

Abstract

The rapid development of pharmacotherapy has resulted in a growing clinical importance for the treatment of the increasing number of women with schizophrenia during pregnancy. An evolving database on reproductive health safety factors for women with schizophrenia has begun to be of assistance in optimising clinical benefits for women with childbearing potential. Given the prevalence of antipsychotic use during pregnancy in women with schizophrenia, it is important for the clinician to have a prepared approach to the administration of these agents. In general, the use of psychotropic medication during pregnancy is indicated when risk to the fetus from exposure to this medication is outweighed by the risks of untreated psychiatric illness in the mother. The preponderance of evidence from registries to large health surveys indicate that treatment with antipsychotic medication confers either no or a small nonspecific risk for organ malformations. According to the relevant literature published on the safety of antipsychotic medication during pregnancy, the findings are encouraging; however, the currently available data are very limited. Until there are more controlled prospective data on the impact of drugs on fetal and later development, the clinician will continue to work in a state of potential uncertainty, weighing partially estimated risks against managing individual clinical problems. The aim for the clinician should be to provide the best information available regarding the scope of possible risks associated with the treatment of schizophrenia during pregnancy. On the basis of the available data, generalisation is impossible and recommendations should be made on a drug-by-drug basis. The risks and benefits must always be carefully weighed for each patient on an individual basis. Only a woman who is well enough to acknowledge her pregnancy and her mental illness can effectively weigh the relative and partially unknown risks of treatment with antipsychotic medication against the highly probable risks of illness exacerbation if untreated.

Integrity signals

Registry

Crossref · 10.2165/00003495-200565090-00002

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Trixler, M., G??ti, ?., Fekete, S., & T??nyi, T.
Affiliations
University of Pecs (HU)
Corresponding author
Trixler, M??ty??s
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2005
Volume
65
Issue
9
Pages
1193-1206
ISSN
0012-6667 (ISSN-L)
DOI
10.2165/00003495-200565090-00002
OpenAlex
W82316989
Cited by
56
References
79
Citations by year
2026: 1 · 2023: 1 · 2022: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 4 · 2013: 5 · 2012: 1
FWCI
1.07
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
Keywords
antipsychotic drugs, schizophrenia, pregnancy, maternal mental illness, drug safety in pregnancy, fetal malformations, risk-benefit assessment, untreated psychosis, psychotropic drugs, individualized treatment decision-making
MeSH terms
Female, Humans, Infant, Newborn, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Prenatal Exposure Delayed Effects, Schizophrenia, Antipsychotic Agents, Practice Guidelines as Topic, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review